Display options
Cite
Nguyen DV, Chu HC, Nguyen DV, et al. HLA-B*1502 and carbamazepine-induced severe cutaneous adverse drug reactions in Vietnamese. Asia Pac Allergy. 2015;5(2):68-77doi: 10.5415/apallergy.2015.5.2.68.
Nguyen, D. V., Chu, H. C., Nguyen, D. V., Phan, M. H., Craig, T., Baumgart, K., & van Nunen, S. (2015). HLA-B*1502 and carbamazepine-induced severe cutaneous adverse drug reactions in Vietnamese. Asia Pacific allergy, 5(2), 68-77. https://doi.org/10.5415/apallergy.2015.5.2.68
Nguyen, Dinh Van, et al. "HLA-B*1502 and carbamazepine-induced severe cutaneous adverse drug reactions in Vietnamese." Asia Pacific allergy vol. 5,2 (2015): 68-77. doi: https://doi.org/10.5415/apallergy.2015.5.2.68
Nguyen DV, Chu HC, Nguyen DV, Phan MH, Craig T, Baumgart K, van Nunen S. HLA-B*1502 and carbamazepine-induced severe cutaneous adverse drug reactions in Vietnamese. Asia Pac Allergy. 2015 Apr;5(2):68-77. doi: 10.5415/apallergy.2015.5.2.68. Epub 2015 Apr 29. PMID: 25938071; PMCID: PMC4415182.
Copy Download .nbib Format: NLM
Share it on

Asia Pac Allergy. 2015 Apr;5(2):68-77. doi: 10.5415/apallergy.2015.5.2.68. Epub 2015 Apr 29.

HLA-B*1502 and carbamazepine-induced severe cutaneous adverse drug reactions in Vietnamese.

Asia Pacific allergy

Dinh Van Nguyen, Hieu Chi Chu, Doan Van Nguyen, Minh Hong Phan, Timothy Craig, Karl Baumgart, Sheryl van Nunen

Affiliations

  1. Department of Allergy and Clinical Immunology, Hanoi Medical University, Hanoi 10000, Vietnam. ; Center of Allergology and Clinical Immunology, Bach Mai Hospital, Hanoi 844, Vietnam. ; Department of Allergy and Clinical Immunology, Royal North Shore Hospital and Sydney Medical School-Northern, The University of Sydney, Sydney, NSW 2065, Australia.
  2. Center of Allergology and Clinical Immunology, Bach Mai Hospital, Hanoi 844, Vietnam.
  3. Department of Allergy and Clinical Immunology, Hanoi Medical University, Hanoi 10000, Vietnam. ; Center of Allergology and Clinical Immunology, Bach Mai Hospital, Hanoi 844, Vietnam.
  4. Outpatients Department, Bach Mai Hospital, Hanoi 844, Vietnam.
  5. Section of Allergy, Asthma and Immunology, Penn State University, Hershey, PA 17033, USA.
  6. Sonic Clinical Institute, Macquarie Park, Sydney, NSW 2113, Australia.
  7. Department of Allergy and Clinical Immunology, Royal North Shore Hospital and Sydney Medical School-Northern, The University of Sydney, Sydney, NSW 2065, Australia.

PMID: 25938071 PMCID: PMC4415182 DOI: 10.5415/apallergy.2015.5.2.68

Abstract

BACKGROUND: In Vietnam, we observed a high incidence of carbamazepine (CBZ)-induced severe cutaneous adverse drug reactions (SCARs)-Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN), and drug-induced hypersensitivity rash with eosinophilia and systemic symptoms (DRESS). In other Asian countries, HLA-B(*)1502 is an established risk factor for SCARs.

OBJECTIVE: The aim of our study was to determine the frequency of HLA-B(*)1502 in SCARs patients at a large University Medical Center in Hanoi, Vietnam.

METHODS: Thirty-eight cases of SCARs caused by CBZ and 25 patients with epilepsy tolerating CBZ were enrolled in a case-controlled study. Clinical manifestations and laboratory findings were recorded for each subject. Genomic DNA was isolated using the QIAamp DNA purification system. The combination of polymerase chain reaction and sequence specific oligonucleotide probes with the Luminex 100×MAP flow cytometry dual laser system was then used to quantitate fluorescently labelled oligonucleotides attached to colour-coded microbeads.

RESULTS: Cases comprised 20 SJS (52.6%), 7 TEN (18.4%), 8 overlap syndrome (21.1%), and 3 DRESS patients (7.9%). A strong association between HLA B(*)1502 and bullous skin reactions such as SJS/TEN and overlap was confirmed with an odds ratio (OR) of 33.78 (95% confidence interval [CI], 7.55-151.03), p < 0.0001, Sensitivity 91.4%, Specificity 76.0%, positive predictive value 84.2%, and negative predictive value 86.4%. We did not, however, observe any correlation between the presence of this allele and CBZ-induced nonbullous skin reactions (DRESS) (OR, 6.33; 95% CI, 0.48-82.74; p = 0.1592).

CONCLUSION: Our results indicate the presence of HLA-B(*)1502 in Vietnamese is a pharmacogenetic risk factor for developing CBZ-induced SJS/TEN.

Keywords: Carbamazepine; Drug-related side effects and adverse reactions; HLA-B antigens; Pharmacogenomics

References

  1. Drug Res (Stuttg). 2015 Feb;65(2):107-11 - PubMed
  2. Pharmacogenet Genomics. 2014 Feb;24(2):94-112 - PubMed
  3. Burns. 2010 Aug;36(5):616-29 - PubMed
  4. Epilepsia. 2010 Dec;51(12):2461-5 - PubMed
  5. Br J Dermatol. 2008 Mar;158(3):640-2 - PubMed
  6. Seizure. 2010 Nov;19(9):562-6 - PubMed
  7. Br J Dermatol. 1997 Oct;137(4):605-8 - PubMed
  8. Int J Dermatol. 2011 Feb;50(2):221-4 - PubMed
  9. Nature. 2004 Apr 1;428(6982):486 - PubMed
  10. Clin Geriatr Med. 2002 Feb;18(1):21-42 - PubMed
  11. Epilepsy Res. 2011 Nov;97(1-2):190-7 - PubMed
  12. Eur J Clin Pharmacol. 2011 Sep;67(9):885-7 - PubMed
  13. JAMA Dermatol. 2013 Sep;149(9):1025-32 - PubMed
  14. Epilepsy Behav. 2010 Nov;19(3):405-8 - PubMed
  15. Arch Dermatol. 2004 Feb;140(2):183-8 - PubMed
  16. Arch Dis Child. 2014 Jun;99(6):581-4 - PubMed
  17. Epilepsy Res. 2008 Aug;80(2-3):194-200 - PubMed
  18. CMAJ. 2010 Mar 23;182(5):476-80 - PubMed
  19. Seizure. 2011 Mar;20(2):160-2 - PubMed
  20. Curr Opin Allergy Clin Immunol. 2010 Aug;10(4):280-90 - PubMed
  21. Toxicology. 2005 Apr 15;209(2):123-9 - PubMed
  22. N Engl J Med. 2011 Mar 24;364(12):1126-33 - PubMed
  23. Ann Allergy Asthma Immunol. 2006 Nov;97(5):698-702 - PubMed
  24. Epilepsia. 2007 May;48(5):1015-8 - PubMed
  25. Pharm World Sci. 2005 Jun;27(3):170-4 - PubMed
  26. N Engl J Med. 2011 Mar 24;364(12):1134-43 - PubMed
  27. J Invest Dermatol. 2000 Aug;115(2):149-53 - PubMed
  28. Epilepsia. 2010 May;51(5):926-30 - PubMed
  29. Indian J Dermatol Venereol Leprol. 2009 Nov-Dec;75(6):579-82 - PubMed
  30. Pharmacogenomics. 2008 Nov;9(11):1617-22 - PubMed
  31. Seizure. 2011 Jul;20(6):446-8 - PubMed
  32. Tissue Antigens. 2008 Feb;71(2):127-34 - PubMed
  33. Pharmacogenomics. 2006 Sep;7(6):813-8 - PubMed
  34. Neurology. 2013 Apr 23;80(17):1621 - PubMed
  35. Epilepsy Res. 2006 Jul;70(1):27-40 - PubMed
  36. Epilepsia. 2008 Dec;49(12):2087-91 - PubMed
  37. Pharmacogenomics. 2008 Oct;9(10):1543-6 - PubMed
  38. Epilepsia. 2007 Jul;48(7):1360-5 - PubMed
  39. J Huazhong Univ Sci Technolog Med Sci. 2014 Feb;34(1):146-50 - PubMed
  40. J Burn Care Res. 2011 Mar-Apr;32(2):237-45 - PubMed
  41. N Engl J Med. 1994 Nov 10;331(19):1272-85 - PubMed

Publication Types